Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by MrMugsyon Jul 25, 2021 4:21pm
240 Views
Post# 33602333

RE:Updates

RE:Updates
Doccole wrote: Hi team Antibe,

not sure Dano can give me much of anything that would make me go wow!  I'm looking for results now.  Promises mean as much as my ex gfs promises.  I know we have a mixed bag on this chat, what can dano and the group give us that will make you go, wow? Other than the obvious sale/partnership.

things I don't trust-
deadlines, progress on drugs, anything to do with Nasdq.

deadlines have been pretty badly timed, regardless of climate.

progress on drugs - I think back about dano and stauffer making it sound like they were about to drop a covid angle. They were so gitty, and then nothing.  This pipeline has been stuck forever.

nasdq- you all know that joke.

Needless to say, I like the science and the market potential.  I have Little trust in the business side.  I've been outspoken on this.  I hope this can eventually change!


Hey Doccole.

I understand your pain.
Not much I want to say here these days as there are individuals reading who really don't deserve any information.

Knowing who to trust and who not to trust is very important and everyone needs to get good at that - considering how much of your cash could be on the line here (or anywhere for that matter).

Personally - it's no longer about deadlines as it is about proving ourselves to Big Pharma.  Got once chance at a first impression and getting Big Pharma interested.

And ... as much as it's about OTENA right now ... it's so much more than that.  I believe we need to guide Big Pharma to that watering hole and force them to drink - that's what I think is happening with each move.

In terms of that giddy COVID angle ... I'm thinking we're knee deep in it and I'm very excited about the possibilities.  There are potentially 3 directions with the COVID drug work but until they have something to share - good or bad - we won't know which of those items are actually on the menu.  Correction ... we might hear about 1 of 3 sooner than later.

Nasdaq isn't a joke - far from it.
I get that you are frustrated but I maintain what I have been saying here for a long time now.
We are not going to the NASDAQ until management sees the upward momentum coming for the share price.  I've already indicated where I think the share price needs to be and where it needs to go as we make our way to a US exchange.  Personally, I think we're getting close to that point.

Yes - the science is great.
All I care right now ... is that Dan is helping Big Pharma understand how great it really is.
All indications are that he's doing that - at least for me.
Hopefully the due dates for OTENA become someone elses problem.

That's why I've been going gungho on the buy side.
I have to thank The Acadamy, my parents and all the sellers who afforded me the chance to purchase more shares.  Hahaha !

Anyway - Head-up Doccole.  The value is rising while the difference between the share price and the value has been widening.  That only last until people realize it ... and ... they close the gap.  Pretty sure the NASDAQ will close that gap qucikly, once we go.

All in my opinion though.  We'll see if I'm right.  Chat about it again in 2022 !!!
<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse